Summary & Overview
CPT 80357: Ketamine and Norketamine Toxicology Assay
CPT code 80357 represents a laboratory toxicology assay for detection and quantitation of ketamine and its primary metabolite norketamine. This code matters nationally because ketamine use spans clinical anesthesia, pain management, and growing off-label psychiatric applications, while nonmedical use and monitoring needs drive demand for targeted drug testing. Accurate coding supports appropriate lab reimbursement, clinical interpretation, and public health surveillance.
Key payers covered in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for ketamine testing, typical sites of service, and the role of this assay in therapeutic monitoring and toxicology screening. The publication summarizes payer coverage patterns and common modifiers encountered in lab billing, highlights coding and billing considerations for laboratories and clinicians, and outlines where to find related codes and documentation guidance.
The content is presented to help billing managers, laboratory directors, and clinicians understand the clinical purpose of the test, expected sites of service, payer landscape, and documentation elements relevant to CPT code 80357. Data not available in the input are identified where applicable.
Billing Code Overview
CPT code 80357 describes a laboratory assay in which the lab analyst measures the amount of or detects the presence of ketamine and norketamine in a patient specimen. This service is a toxicology drug test that quantifies parent drug and metabolite levels to support clinical care, forensic evaluation, or therapeutic monitoring.
-
Service type: Laboratory toxicology assay for ketamine and norketamine
-
Typical site of service: Clinical laboratory, hospital laboratory, or reference/toxicology testing facility
Clinical & Coding Specifications
Clinical Context
A patient presents to an outpatient clinical laboratory or hospital inpatient unit following administration of ketamine for anesthesia, procedural sedation, pain management, or in the context of suspected illicit drug exposure. Typical scenarios include: a perioperative patient receiving ketamine as an induction or adjunct agent where plasma or urine levels are required for therapeutic drug monitoring or medicolegal documentation; an emergency department patient with altered mental status where toxicology confirms ketamine and its primary metabolite norketamine; or a chronic pain clinic patient undergoing monitoring during off-label ketamine infusion therapy.
The clinical workflow: the ordering clinician (anesthesiologist, emergency physician, pain specialist, or intensivist) places an order for ketamine/norketamine quantitative or qualitative testing. Phlebotomy or urine collection is performed and the specimen is sent to the clinical laboratory. The laboratory analyst performs the assay, commonly using mass spectrometry or immunoassay methods, to detect and/or quantify ketamine and norketamine. Results are reported to the ordering provider and documented in the medical record to inform clinical management, confirm exposure, evaluate metabolism or clearance, or support forensic/toxicology purposes. Typical sites of service include outpatient laboratories, hospital clinical laboratories, emergency departments, inpatient wards, and specialty infusion centers.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Unmodified procedure |